Baygam, gamastan s/d, Kiovig(human immunoglobulin g)
Human immunoglobulin g is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Asceniv, Baygam, gamastan s/d, Bivigam, Cutaquig, Cuvitru, Flebogamma , flebogamma dif, Gammagard liquid, Gammagard, gammagard s/d, iveegam, Gammaplex, Hizentra, Hyqvia, Octagam, Panzyga, Privigen, Xembify (discontinued: Carimune, carimune nf, panglobulin, sandoglobulin, Flebogamma , flebogamma dif, Gamimune, Gammagard, gammagard s/d, iveegam, Gammaplex, Gammar i.v.,gammar-p, Vivaglobin)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Immune globulin (human)
Immune globulin intravenous (human)
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Bivigam | Immune Globulin Intravenous (Human) | ADMA Biologics | A-125389 RX | 2012-12-19 | 2 products |
| Gammaplex | Immune Globulin Intravenous (Human) | Bio Products Laboratory | A-125329 RX | 2017-02-06 | 3 products |
| Flebogamma 5%, Flebogamma 5% Dif | Immune Globulin Intravenous (Human) | Grifols | A-125077 RX | 2003-12-15 | 3 products |
| Octagam | Immune Globulin Intravenous (Human) | Octapharma | A-125062 RX | 2004-05-21 | 9 products |
| Panzyga | Immune Globulin Intravenous (Human)-ifas | Octapharma | A-125587 RX | 2018-08-02 | 6 products |
| Gammagard, Gammagard S/D, Iveegam | Immune Globulin Intravenous (Human) | Takeda | A-103133 RX | 2000-07-27 | 2 products |
Show 7 discontinued
Immune globulin infusion (human)
Immune globulin subcutaneous (human)
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Cutaquig | Immune Globulin Subcutaneous (Human)-hipp | Octapharma | A-125668 RX | 2018-12-12 | 6 products |
Show 1 discontinued
Immune globulin intravenous (human)
+
10% liquid
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Privigen | Immune Globulin Intravenous (Human), 10% Liquid | CSL Behring | A-125201 RX | 2007-07-26 | 5 products |
Immune globulin subcutaneous (human)
+
20% liquid
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Hizentra | Immune Globulin Subcutaneous (Human), 20% Liquid | CSL Behring | A-125350 RX | 2010-03-04 | 5 products |
Immune globulin infusion (human)
+
10% with recombinant human hyaluronidase
Immune globulin intravenous
+
human
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Asceniv | Immune Globulin Intravenous, Human-slra | ADMA Biologics | A-125590 RX | 2019-04-01 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| antivenin (micrurus fulvius) | Biologic Licensing Application | 2001-08-31 |
| antivenin (micrurus fulvius) north american coral snake antivenin (equine) | Biologic Licensing Application | 2017-04-05 |
| asceniv | Biologic Licensing Application | 2025-05-06 |
| atgam | Biologic Licensing Application | 2015-04-13 |
| babybig | Biologic Licensing Application | 2024-12-05 |
| bivigam | Biologic Licensing Application | 2025-05-05 |
| cnj-016 | Biologic Licensing Application | 2025-06-18 |
| flebogamma | Biologic Licensing Application | 2010-01-07 |
| flebogamma dif | Biologic Licensing Application | 2006-11-01 |
| gamastan s/d | Biologic Licensing Application | 2010-10-28 |
Show 15 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acidosis | EFO_1000014 | D000138 | E87.2 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
4022 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 346 | 180 | 18 | 2 | 16 | 436 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 116 | 148 | 45 | 1 | 22 | 289 |
| Lymphoma | D008223 | — | C85.9 | 100 | 169 | 25 | 1 | 16 | 274 |
| Non-small-cell lung carcinoma | D002289 | — | — | 132 | 135 | 20 | 1 | 4 | 224 |
| Leukemia | D007938 | — | C95 | 68 | 125 | 15 | 2 | 15 | 190 |
| Colorectal neoplasms | D015179 | — | — | 85 | 70 | 8 | 2 | 7 | 138 |
| Myelodysplastic syndromes | D009190 | — | D46 | 40 | 87 | 6 | 1 | 10 | 128 |
| Covid-19 | D000086382 | — | U07.1 | 26 | 56 | 34 | 3 | 27 | 126 |
| Multiple myeloma | D009101 | — | C90.0 | 53 | 74 | 8 | 1 | 10 | 124 |
| Lung neoplasms | D008175 | — | C34.90 | 56 | 77 | 14 | 1 | 5 | 123 |
Show 187 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 86 | 95 | 17 | — | 8 | 172 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 65 | 87 | 13 | — | 9 | 150 |
| Melanoma | D008545 | — | — | 89 | 74 | 3 | — | 4 | 132 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 58 | 60 | 10 | — | 3 | 105 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 44 | 57 | 8 | — | 3 | 100 |
| Adenocarcinoma | D000230 | — | — | 42 | 57 | 9 | — | 4 | 96 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 41 | 57 | 4 | — | 5 | 93 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 56 | 56 | 10 | — | 3 | 91 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 40 | 57 | 5 | — | 4 | 91 |
| Follicular lymphoma | D008224 | — | C82 | 35 | 54 | 6 | — | 5 | 87 |
Show 346 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Waldenstrom macroglobulinemia | D008258 | — | C88.0 | 12 | 21 | — | — | 3 | 32 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 8 | 21 | — | — | 3 | 30 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 15 | 20 | — | — | 2 | 29 |
| Esophageal neoplasms | D004938 | — | C15 | 16 | 15 | — | — | 1 | 23 |
| Cholangiocarcinoma | D018281 | — | C22.1 | 9 | 18 | — | — | — | 23 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 7 | 9 | — | — | 3 | 18 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 7 | 8 | — | — | 3 | 18 |
| Cutaneous malignant melanoma | D000096142 | — | — | 10 | 13 | — | — | — | 18 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 9 | 9 | — | — | — | 17 |
| Mesothelioma | D008654 | — | C45 | 10 | 9 | — | — | — | 17 |
Show 371 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv-2 | D015498 | — | — | 2 | — | — | — | 1 | 3 |
| Chickenpox | D002644 | EFO_0007204 | B01 | 1 | — | — | — | 2 | 3 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | — | — | — | 2 | 3 |
| Pharyngeal neoplasms | D010610 | — | C14.0 | 2 | — | — | — | — | 2 |
| Rhabdoid tumor | D018335 | — | — | 2 | — | — | — | — | 2 |
| Rectal diseases | D012002 | — | — | 2 | — | — | — | — | 2 |
| Intestinal diseases | D007410 | — | K63.9 | 2 | — | — | — | — | 2 |
| Hyperglycemia | D006943 | — | R73.9 | 2 | — | — | — | — | 2 |
| Dermatofibrosarcoma | D018223 | — | — | 2 | — | — | — | — | 2 |
| Muscular diseases | D009135 | EFO_0002970 | G72.9 | 1 | — | — | — | 1 | 2 |
Show 107 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syphilis | D013587 | EFO_0007504 | A53.9 | — | — | — | — | 4 | 4 |
| Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | — | — | — | 3 | 3 |
| Necrotizing enterocolitis | D020345 | EFO_0003928 | K55.3 | — | — | — | — | 3 | 3 |
| Herpes zoster | D006562 | EFO_0006510 | B02 | — | — | — | — | 3 | 3 |
| Nerve block | D009407 | — | — | — | — | — | — | 2 | 2 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | — | — | — | 2 | 2 |
| Takayasu arteritis | D013625 | EFO_1001857 | M31.4 | — | — | — | — | 2 | 2 |
| Aortic arch syndromes | D001015 | — | — | — | — | — | — | 2 | 2 |
| Antiphospholipid syndrome | D016736 | EFO_0002689 | D68.61 | — | — | — | — | 2 | 2 |
| Herpes simplex | D006561 | — | B00 | — | — | — | — | 2 | 2 |
Show 147 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Human immunoglobulin g |
| INN | _ |
| Description | Immune globulin (human) |
| Classification | Unknown |
| Drug class | antineoplastics (mitotic inhibitors; tubulin binders) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201599 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 66Y330CJHS (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Panzyga – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
No data
Safety
Black-box Warning
Black-box warning for: Asceniv, Atgam, Bivigam, Cnj-016, Flebogamma, Gammagard liquid, Gammaplex, Gamunex-c, Privigen, Rhophylac
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
91,371 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use